Cothera Bioscience was formed by the founding core members of CrownBio, a well-known Contract Research Organization specializing in oncology, to develop innovative, targeted cancer therapies.
Cothera Bioscience has developed a series of new product pipelines for cancer in the areas of synthetic lethality and immunotherapy, and has filed a number of international and domestic patents for its R&D results.
Zotiraciclib (ZTR/TG02) is the second compound Cothera Bioscience has developed to treat MYC-mutated tumors. ZTR is a highly potent oral CDK9 inhibitor which can cross the blood–brain barrier and degrade proteins with short half-lives and anti-apoptotic oncogenes such as McL-1 and Myc. The compound is being developed for the treatment of high-grade glioma (HGG) and diffuse intrinsic pontine glioma (DIPG). A Phase 1b clinical trial of ZTR sponsored and conducted by the National Cancer Institute (NCI) in the US has just completed, which has initially confirmed the safety and efficacy of ZTR in combination with temozolomide (TMZ) in the treatment of patients with relapsed high-grade glioma, and a Phase II international multi-center clinical trial is about to begi